WebFilter products: Health Area. Animal Health Human Health. Health Areas. Indications For Humans. Atrial Fibrilation BOPD (Borderline) COPD & Asthma Depression Diabetes Gastrointestinal Cancer GPP Heart Failure Hypertension Kidney Diseases Lung Cancer Lung Fibrosis Melanoma NASH Obesity Schizophrenia Stroke. All Indications. Webprescribed for AFib patients because their irregular heartbeats can cause blood to collect in the heart and form a clot that can travel to the brain, cutting off the oxygen and blood supply, causing a stroke. About one in seven people who have a stroke has AFib. The more conventional anticoagulants are warfarin (Coumadin) and heparin.
JCM Free Full-Text Cerebrovascular, Cognitive and Cardiac …
WebBoehringer Ingelheim's Portal for HealthCare Professionals. Boehringer Ingelheim has been family-owned since its foundation in 1885 and is one of the 20 largest companies in … WebDabigatran. Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. [3] [4] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. [3] オレンジネット ポスティング
Boehringer Ingelheim and Medtronic shed light on Atrial …
WebApr 6, 2024 · 1 INTRODUCTION. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and remains one of the major causes of stroke, transient ischemic attack, and heart failure. 1, 2 Despite improvements in rhythm control interventions, there is still a considerable risk of mortality, AF-related stroke, frequent … WebMar 6, 2014 · Boehringer Ingelheim led the anticoagulant field by bringing Pradaxa®, the first NOAC for stroke prevention in atrial fibrillation, to market.(20) Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role in this patient population,(4) in addition to over 2.7 million patient-years of ... WebPatients with an irregular heart beat (known as atrial fibrillation) are at increased risk of stroke. Preventing stroke in these patients is a key focus of our cardiovascular team. Boehringer Ingelheim developed the first non-vitamin K antagonist oral anticoagulant … 1 in 5. Atrial fibrillation (AF) is the most common cardiac rhythm disorder … オレンジネット ピン